Possible involvement of brain prostaglandin E2 and prostanoid EP3 receptors in prostaglandin E2 glycerol ester-induced activation of central sympathetic outflow in the rat. 2014

Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
Department of Pharmacology, Kochi University School of Medicine, Nankoku, Kochi 783-8505, Japan. Electronic address: shimizu@kochi-u.ac.jp.

We recently reported that intracerebroventricularly administered 2-arachidonoylglycerol elevated plasma noradrenaline and adrenaline by brain monoacylglycerol lipase- (MGL) and cyclooxygenase-mediated mechanisms in the rat. These results suggest that 2-arachidonoylglycerol is hydrolyzed by MGL to free arachidonic acid, which is further metabolized to prostaglandins (PGs) by cyclooxygenase in the brain, thereby elevating plasma noradrenaline and adrenaline. On the other hand, 2-arachidonoylglycerol can be also metabolized by cyclooxygenase to PG glycerol esters (PG-Gs), which seems to be hydrolyzed by MGL to free PGs. Here, we examined the involvement of brain PG-Gs in the elevation of plasma noradrenaline and adrenaline regarding PGE2-G and prostanoid EP receptors using anesthetized male Wistar rats. Intracerebroventricularly administered PGE2-G (1.5 and 3 nmol/animal) dose-dependently elevated plasma noradrenaline but not adrenaline. PGE2-G also elevated systolic, mean and diastolic blood pressure and heart rate. The PGE2-G-induced elevation of plasma noradrenaline was attenuated by JZL184 (MGL inhibitor). Intracerebroventricularly administered PGE2 (0.3 and 1.5 nmol/animal) and sulprostone (0.1 and 0.3 nmol/animal) (EP1/EP3 agonist) also elevated plasma noradrenaline but not adrenaline in a dose-dependent manner. The sulprostone-induced elevation was attenuated by L-798,106 (EP3 antagonist), but not by SC-51322 (EP1 antagonist). L-798,106 also attenuated the PGE2-G- and PGE2-induced elevation of plasma noradrenaline, while PF-04418948 (EP2 antagonist) and L-161,982 (EP4 antagonist) had no effect on the PGE2-G-induced response. These results suggest a possibility that brain PGE2-G produced from 2-arachidonoylglycerol can be hydrolyzed to free PGE2, thereby activating central sympathetic outflow by brain prostanoid EP3 receptor-mediated mechanisms in the rat.

UI MeSH Term Description Entries
D008297 Male Males
D008994 Monoacylglycerol Lipases An enzyme that catalyzes the hydrolysis of glycerol monoesters of long-chain fatty acids EC 3.1.1.23. Glycerol Monoester Hydrolase,Glycerol Monoester Hydrolases,Monoacylglycerol Lipase,Monoglyceride Esterase,Monoglyceride Esterases,Monoglyceride Lipase,Monoglyceride Lipases,Monoglyceride Hydrolase,Esterase, Monoglyceride,Esterases, Monoglyceride,Hydrolase, Glycerol Monoester,Hydrolase, Monoglyceride,Hydrolases, Glycerol Monoester,Lipase, Monoacylglycerol,Lipase, Monoglyceride,Lipases, Monoacylglycerol,Lipases, Monoglyceride,Monoester Hydrolase, Glycerol,Monoester Hydrolases, Glycerol
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010880 Piperidines A family of hexahydropyridines.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D002491 Central Nervous System Agents A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252) Central Nervous System Drugs
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
February 2011, The Journal of pharmacology and experimental therapeutics,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
November 1994, Brain research,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
June 2011, European journal of pharmacology,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
March 2009, British journal of pharmacology,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
June 1992, Prostaglandins,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
March 2012, The Journal of pharmacology and experimental therapeutics,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
January 2002, Journal of neuroendocrinology,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
January 1995, Naunyn-Schmiedeberg's archives of pharmacology,
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
December 2019, Hypertension (Dallas, Tex. : 1979),
Takahiro Shimizu, and Kenjiro Tanaka, and Kumiko Nakamura, and Keisuke Taniuchi, and Toshio Yawata, and Youichirou Higashi, and Tetsuya Ueba, and Fotios Dimitriadis, and Shogo Shimizu, and Kunihiko Yokotani, and Motoaki Saito
January 2014, PloS one,
Copied contents to your clipboard!